7 : Reemerging Infections: Recent Developments in Pertussis

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in

Reemerging Infections: Recent Developments in Pertussis, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap07-1.gif /docserver/preview/fulltext/10.1128/9781555816957/9781555811419_Chap07-2.gif


Although pertussis (whooping cough) technically qualifies as a reemerging infection by virtue of its increase in reported cases over the last 15 years, there is no doom and gloom about the future of this fascinating illness. Despite the important recent progress summarized in this chapter, there are substantial barriers to overcome in the long-term mission of controlling or eliminating the disease. A variety of primers have been used for pertussis polymerase chain reaction (PCR) assays, and this technology is available in an increasing number of centers. Serology is also being used increasingly to identify patients with pertussis, although this approach is more effective for epidemiologic purposes than in acute diagnosis. This infection is localized to the respiratory tract. Almost certainly, reaches that site via aerosol droplets produced by the cough of an actively infected individual. Immunization with whole cell pertussis vaccine has been the mainstay of public health measures against this illness since the mid-1950s. Future clinical investigation will focus on potential benefit of additional antigens for the acellular vaccines, their duration of protection, and whether they might be used for protection of the adult population which is now recognized as experiencing an increasing incidence of pertussis.

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7
Highlighted Text: Show | Hide
Loading full text...

Full text loading...


1.Anonymous. 1988. Placebo-controlled trial of two acellular pertussis vaccines in Sweden-protective efficacy and adverse events. Lancet i: 955960.
2.Anonymous. 1991. In C. P. Howson,, C. J. Howe,, and H. V. Fineberg (ed.), Adverse Effects of Pertussis alld Rubella Vaccines. National Academy Press, Washington. D.C..
3.Anonymous. 1991. WHO meeting on case definition of pertussis. World Health Organization. Geneva, Switzerland.
4.Anonymous. 1993. Resurgence of pertussis-United States, 1993. Morbid. Mortal. Weekly Rep. 42: 952 960.
5.Anonymous. 1994. In K. R. Stratton,, C. J. Howe,, and R. B. Johnston (ed.), DPT Vaccine and Chronic Nervous System Dysfunction: a new Analysis. Nationa1 Academy Press, Washington, D.C..
6.Anonymous. 1997. Proceedings of International Symposium on Pertussis Vaccine Trials. October 30-November I, 1995; Rome, Italy. Dev. Biol. Stand. 89: 1 410.
7.Anonymous. 1996. Food and Drug Administration approval of an acellular pertussis vaccine for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. Morbid. Mortal. Weekly Rep. 45: 676677.
8.Anonymous. 1997. Pertussis outbreak-Vennont, 1996. Morbid. Mortal. Weekly Rep. 46: 822 826.
9.Anonymous. 1997. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbid. Mortal. Weekly Rep. 46: 125.
10. Aoyama, T.,, Y. Takeuchi,, A. Golo,, H. Iwai,, Y. Murase,, and T. Iwata. 1992. Pertussis in adults. Am. J. Dis. Child. 146: 163 166.
11. Arico, B.,, and R. Rappuoli. 1987. Bordetella parapertussis and Bordetella brollchiseptica contain transcriptionally silent pertussis toxin genes. J. Bacteriol. 169: 2847 2853.
12. Berggard, K.,, E. Johnsson,, F. R. Mooi,, and G. Lindahl. 1997. Bardetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect. lmmun. 65: 3638 3643.
13. Birkebaek, N. H.,, I. Heron,, and K. Skjodt. 1994. Bordetella pertussis diagnosed by polymerase chain reaction. APMIS 102: 291 294.
14. Black, S. 1997. Epidemiology of pertussis. Pediatr Infect. Dis. J. 16: S85 89.
15. Brennan, M. J .,, and R. D. Shahin. 1996. Pertussis antigens that abrogate bacterial adherence and elicit immunity. Am. J. Respir. Crit. Care Med. 154: SI45 149.
16. Bromberg, K.,, H. Mendez,, and E. Handelsman. 1995. Chronic infection with B. pertussis (BP) in HIV-infected children. Pediatr. Res. 37: 107A. (Abstract 1008.).
17. Bromberg, K.,, G. Tannis,, and P. Steiner. 1991. Detection of Bordelella pertussis associated with the alveolar macrophages of children with human immunodeficiency virus infection. Infect. lmmun. 59: 4715 4719.
18. Cassone, A.,, C. M. Ausi.lIo, F. Urbani, R. Lande, M. Giuliano, A. La Sala, A. Piscitelli, and S. Salmaso. 1997. Cell· mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch. Pedialr. Adolesc. Med. 151: 283 289.
19. Cheers, C.,, and D. F. Gray. 1969. Macrophage behaviour during the complaisant phase of murine pertussis. Immunology 17: 875 887.
20. Cherry, J. D. 1984. The epidemiology of pertussis and pertussis immunization in the United Kingdom and the United States: a comparative study. Curr. Probl. Pediatr. 14: 1 78.
21. Cherry, J. D. 1997. Comparative efficacy of a cellular pertussis vaccines: an analysis of recent trials. Pediatr. lnfect. Dis. J. 16: S90 96.
22. Cherry, J. D.,, L. J. BaralT,, and E. Hewlett. 1989. The past, present, and future of pertussis. The role of adults in epidemiology and future control. West. J. Med. 150: 319 328.
23. Cherry, J. D.,, P. A. Brunell,, G. S. Golden,, and D. Karzon. 1988. Report of the task force on pertussis and pertussis vaccine. Pediatrics 81: 939 984.
24. Cimolai, N.,, C. Trombley,, and D. O'Neill. 1996. Diagnosis of whooping cough: a new era with rapid molecular diagnostics. Pediatr. Emerg. Care 12: 91 93.
25. Confer, D. L.,, and J. W. Eaton. 1982. Phagocyte impotence caused by an invasive bacterial adenylkate cyclase. Science 217: 948 950.
26. Cookson, B. T.,, A. N. Tyler,, and W. E. Goldman. 1989. Primary structure of the peptidoglycan-derived tracheal cytotox:in of Bordetella pertussis. Biochemistry 28: 1744 1749.
27. Deville, J. G.,, J. D. Cherry,, P. D. Christenson,, E. Pineda,, C. T. Leach,, T. L. KuhIs,, and S. Viker. 1995. Frequency of unrecognized Bordetella pertussis infections in adults. Clin. Infect. Dis. 21: 639 642.
28. Douglas, E.,, J. G. Coote,, R. Parton,, and W. McPheat. 1993. Identification of Bordetella pertussis in nasopharyngeal swabs by PCR amplification of a region of the adenylate cyclase gene. J. Med. Microbiol. 38: 140 144.
29. Edelman, K.,, S. Nikkari,, O. Ruuskanen,, Q. He,, M. Viljanen,, and J. Mertsol, 1996. Detection of Bordetella pertussis by polymerase chain reaction and culture in the nasopharynx of erythromycin-treated infants with pertussis. Pediatr. Infect. Dis. J. 15: 54 57.
30. Edwards, K. M. 1993. Acellular pertussis vaccines-a solution to the pertussis problem? J. lnfect. Dis. 168: 15 20.
31. Ewanowich, C. A.,, A. R. Melton,, A. A. Weiss,, R. K. Sherburne,, and M. S. Peppler. 1989. Invasion of HeLa 229 cells by virulent Bordetella pertussis. lnfect. lmmun. 57: 2698 2704.
32.. Finn, T. M.,, and L. A. Stevens. 1995. Tracheal colonization factor: a Bordetella pertussis secreted virulence determinant. Mol. Microbial. 16: 625 634.
33. Friedman, R. I.,, K. Nordensson,, L. Wilson,, E. T. Akporiaye,, and D. E. Yocum. 1992. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60: 4578 4585.
34. Glare, E. M.,, J. C. Paton,, R. R. Premier,, A. J. Lawrence,, and I. T. Nisbet. 1990. Analysis of a repetitive DNA sequence from Bordetella pertussis and its application to the diagnosis of pertussis using the polymerase chain reaction. J. Clin. Microbial. 28: 1982 1987.
34.a. Goldman, W. E. Personal communication.
35. Goodwin, M. S.,, and A. A. Weiss. 1990. Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect. lmmun. 58: 3445 3447.
36. Greco, D.,, S. Salmaso,, P. Mastrantonio,, M. Giuliano,, A. E. Tozzi,, A. Anemona,, M. L. Ciofi degli Atti,, A. Giammanco,, P. Panei,, W. C. Blackwelder,, D. L. Klein,, and S. G. F. Wassilak. 1996. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N. Engl. J. Med. 334: 341 348.
37. Grimprel, E.,, P. Begue,, I. Anjak,, F. Betson,, and N. Guiso. 1993. Comparison of polymerase chain reaction, culture, and western immunoblot serology for diagnosis of Bordetella pertussis infection. J. Clin. Microbiol. 31: 2745 2750.
38. Gross, R.,, and N. H. Carbonettl. 1993. Differential regulation of Bordetella pertussis virulence factors. Zentralbl Bakteriol. 278: 177 186.
39. Gustafsson, L.,, H. O. Ha!lander,, P. Olin,, E. Reizenstcin,, and J. Storsaeter. 1996. A controlled trial of a two-component acellular, a five-component aceHular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334: 349 355.
40. Halperin, S. A.,, and T. J. Marrie. 1991. Pertussis encephalopathy in an adult: case report and review. Rev. Infect. Dis. 13: 1043 1047.
41. He, Q.,, J. Mertsola,, H. Soini,, and M. K. Viljanen. 1994. Sensitive and specific polymerase chain reaction assays for detection of Bordetella pertussis in nasopharyngeal specimens. J. Pediatr. 124: 421 426.
42. Heiss, L. N.,, J. R. Lancaster, Jr., J. A. Corbett, and W. E. Goldman. 1994. Epithelial autotoxicity of nitric oxide: role in the respiratory cytopathology of pertu ssis. Proc. Natl. Acad. Sci. USA 91: 267 270.
43. Herwaldt, L. A. 1993. Pertussis and pertussis vaccines in adults. JAMA 269: 93 94.
44. Hewlett, E. L., 1995. Bordetella species, p. 2078 2084. In G. L. Mandell,, J. E. Bennett,, and R. Dolin (ed.), Principles and Practices of Infectious Diseases, 4th ed. Churchill Livingstone, New York. N.Y..
45. Hewlett, E. L., 1996. Bordetella pertussis and the central nervous system. p. 655 666. In W. M. Scheid,. R. J. Whitley,, and D. T. Durack (ed.). Infections of the Central Nervous System, 2nd ed. Raven Press, New York, N.Y..
46. Hewlett, E. L. 1997. Pertussis: current concepts of pathogenesis and prevention. Pediatr. Infect. Dis. J. 16: 578 84.
47. Hewlett, E. L. 1997. Preparation and composition of acellular pertussis vaccines. Consideration of potential effects on vaccine efficacy. Dev. Biol. Stand. 89: 143 151.
48. Hewlett, E. L., New developments in pertussis, p. 1 12. In G. L. Mandell,, J. E. Bennett,, and R. Dolin (ed.). Principles and Practice of Infectious Diseases Update, vol. 5, no. 2. Churchill Livingstone, New York, N.Y..
49. Hewlett, E. L.,, and J. D. Cherry,. 1997. New and improved vaccines against pertussis, p. 387 416. In G. S. Cohon,, J. B. Kaper,, G. C. Woodrow,. and M. M. Levine (ed.), New Generation Vaccines, 2nd ed. Marcel Dekker, Inc., New York. N.Y..
50. Hewlett, E. L., and V. M. Gordon,. 1988. Adenylate cyclase toxin of Bordetella pertussis, p. 193 209. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, New York, N.Y..
51. Hodder, S. L.,, and E. A. Mortimer, Jr. 1992. Epidemiology of penussis and reactions to pertussis vaccine. Epidemiol. Rev. 14: 243 267.
52. Hoppe, J. E.,, and C. G. Simon. 1990. In vitro susceptibilities of Bordelella pertussis and Bordetella parapertussis to seven ftuoroquinolones. Antimicrob. Agents Chemother. 34: 2287 2288.
53. Houard, S.,, C. Hackel,, A. Herzog,, and A. Bollen. 1989. Specific identification of Bordetella pertussis by the polymerase chain reaction. Res. Microbial. 140: 477 487.
54. Kendrick, P. L.,, G. Eldering,, M. K. Dixon,, and J. Misner. 1947. Mouse protection tests in the study of pertussis vaccine: a comparative series using the intracerebral route of challenge. Am. J. Public Health 37: 803 810.
55. Khelef, N.,, C.·M. Bachelet,, B. B. Vargaftig,, and N. Guiso. 1994. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62: 2893 2900.
56. Khelef, N.,, and N. Guiso. 1995. Induction of macrophage apoptosis by Bordetella pertussis adenylate cyclase-hemolys is. FEMS Microbial. Lett. 134: 27 32.
57. Klein, D. L. 1995. Report of the nationwide multicenter acellular pertussis trial. Pediatrics 96: 547 603.
58. Krantz, I.,, R. Sekura,, B. Trollfors,, J. Taranger,, G. Zackrisson,, T. Lagergard,, R. Schneerson,, and J. Robbins. 1990. Immunogenicity and safety of a pertussis vaccine composed of pertussis toxin inactivated by hydrogen peroxide. in 18- to 23-month -old children. J. Pediatr. 116: 539 543.
59. Lewis, K.,, M. A. Saubolle,, F. C. Tenover,, M. F. Rudinsky,, S. D. Barbour,, and J . D. Cherry. 1995. Pertussis caused by an erythromycin-resistant strain of Bordetella pertussis. Pediatr. Infect. Dis. J. 14: 388 391.
60. Li. Z.,, D. L. Jansen,, T. M. Finn,, S. A. Halperin,, A. Kasina,, S. P. O'Connor,, T. Aoyama,, C. R. Manclark,, and M. J. Brennan. 1994 . Identification of Bordetella pertussis infection by shared-primer PCR. J. Clin. Microbiol. 32: 783 789.
61. Lichtinghagen, R.,, R. Diedrich-Glaubitz,, and B. von Horsten. 1994. Identification of Borderella pertussis in nasopharyngeal swabs using the polymerase chain reaction: evaluation of detection methods. Eur J. Clin. Chem. Clin. Biochem. 32: 161 167.
62. Liese, J. G.,, C. K. Meschievitz,, E. Harzer,, J. Froeschle,, P. Hosbach,, J . E. Hoppe,, F. Porter,, S. Stojanov,, K. Niinivaara,, A. M. Walker,, and B. H. Belohradsky. 1997. Efficacy of a two-component acellular pertussis vaccine in infants. Pediatr. Infect. Dis. J. 16: 1038 1044.
63. Luker, K. E.,, J . L. Collier,, E. W. Kolodziej,, G. R. Marshall,, and W. E. Goldman. 1993. Bordetella pertussis tracheal cytotoxin and other muramyl peptides: distinct structure-activity relationships for respiratory epithelial cytopathology. Proc. Natl. Acad. Sci. USA. 90: 2365 2369.
64. Luker, K. E.,, A. N. Tyler,, G. R. Ma rshall,, and W. E. Goldman. 1995. Tracheal cytotoxin structural requirements for respiratory epithelial damage in pertussis. Mol. Microbiol. 16: 733 743.
65. Marwick, C. 1996. Acellular pertussis vaccine is licensed for infants. JAMA 276: 516 518.
66. Meade, B. D.,, and A. Bollen. 1994. Recommendations for use of the polymerase chain reaction in the diagnosis of Bordetella pertussis infections. J. Med. Microbiol. 41: 51 55.
67. Meade, B. D.,, A. Deforest,, K. M. Edwards,, T. A. Romani,, F. Lynn,, C. H. O'Brien,, C. B. Swartz,, G. F. Reed,, and M. A. Deloria. 1995. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 96: 570 575.
68. Miller, J. F.,, J. J. Mekalanos,, and S. Falkow. 1989. Coordinate regulation and sensory transduction in the control of bacterial virulence. Science 243: 916 922.
69. Miller, J . J., Jr.,, R. J. Silverberg,, T. M. Saito,, and J. B. Humber. 1943. An agglutinative reaction for Hemophilus pertussis.II. Its relation to clinical immunity. J. Pediatr. 22: 644 651.
70. Mills, K. H.,, A. Barnard,, J . Watkins,, and K. Redhead. 1993. Cell-mediated immunity to Bordetella pertussis: role of ThI cells in bacterial clearance in a murine respiratory infection model. Infect Immun. 61: 399 410.
71. Mills, K. H. G.,, M. Ryan,, E. Ryan,, and B. P. Mahon. 1998. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against Bordetella pertussis. Infect. Immun. 66: 594 602.
72. Mink, C. M.,, J. D. Cherry,, P. Christenson,, K. Lewis,, E. Pineda,, D. Shlian,, J. A. Dawson,, and D. A. Blumberg. 1992. A search for Bordettdla pertussis infection in university students. Clin. Infect. Dis. 14: 464 471.
73. Mink, C. M.,, C. H. O' Brien,, S. Wassilak,, A. Deforest,, and B. D. Meade. 1994. Isotype and antigen specificity of pertussis agglutinins following whole-cell pertussis vaccination and infection with Bordetella pertussis. Infect. Immun. 62: 1118 1120.
74. Mink, C. M.,, N. M. Sirota,, and S. Nugent. 1994. Outbreak of pertussis in a fully immunized adolescent and adult population. Arch. Pediatr: Ado/esc. Med. 148: 153 157.
75. Mortimer, E. A., Jr. 1990. Pertussis and its prevent ion: a family affair. J. Infect. Dis. 161: 473 479.
76. Nelson, S.,, A. Matlow,, C. McDowell,, M. Roscoe,, M. Karmali,, L. Penn,, and L. Dyster. 1997. Detection of Bordetella pertussis in clinical specimens by PCR and a microtiter plate-based DNA hybridization assay. J. Clin. Microbial. 35: 117 120.
77. Nencioni, L.,, G. Volpini,, S. Peppoloni,, M. Bugnoli,, T. DeMagistris,, I. Marsili,, and R. Rappuoli. 1991. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment Infect. Immun. 59: 625 630.
78. Parton, R. 1996. New perspectives on Bordetella pathogenicity. J. Med. Microbiol. 44: 233 235.
79. Pearson, R. D.,, P. Symes,, M. Conboy,, A. A. Weiss,, and E. L. Hewlett. 1987. Inhibition of monocyte oxidative responses by Bordetella pertussis adenylate cyclase toxin. J. Immunol. 139: 2749 2754.
80. Pittman, M. 1984. The concept of pertussis as a toxin· mediated disease. Pediatr. Infect. Dis. 3: 467 486.
81. Postels-Multani, S.,, H. J. Schmitt,, C. H. Wirsing von Konig,, H. L. Bock,, and H. Bogaerts. 1995. Symptoms and complications of pertussis in adults. Infection 23: 139 142.
82. Rappuoli, R. 1994. Pathogenicity mechanisms of Bordetella. Curr. Top. Microbial. Immunol. 192: 319 336.
83. Rappuoli, R. 1997. Rational design of vaccines. Nat. Med. 3: 374 376.
84. Redhead, K.,, J. Watkins,, A. Barnard,, and K. H. G. Mills. 1993. Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity. Infect. lmmun. 61: 3190 3198.
85. Reizenstein, E.,, B. Johansson,, L. Mardin,, J. Abens,, R. Mollby,, and H. O. Hallander. 1993. Diagnostic evaluation of polymerase chain reaction discriminative for Bordetella pertussis, B. parapertussis, and B. bronchiseptica. Diagn. Microbiol. lnfect. Dis. 17: 185 191.
86. Reizenstein, E.,, L. Lindberg,, R. Miillby,, and H. O. Hallander. 1996. Validation of nested Bordetella PCR in pertussis vaccine trial. J. Clin. Microbiol. 34: 810 815.
87. Ryan, M.,, G. Murphy,, L. Gothefors,, L. Nilsson,, J. Storsaeter,, and K. H. G. Mills. 1997. Bordetella pertussis respiratory infection in children is associated wilh preferential activation of type I T helper cells. J. Infect. Dis. 175: 1246 1250.
88. Sako, W. 1947. Studies on pertussis immunization. J Pediatr. 30: 29 40.
89. Sato, Y.,, M. Kimura,, and H. Fukumi. 1984. Development of a pertussis component vaccine in Japan. Lancet 1: 122 126.
90. Scarlato, V.,, B. Arico,, A. Prugnola,, and R. Rappuoli. 1991. Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. EMBO J. 10: 3971 3975.
91. Sehmitt, H. J.,, C. H. W. von Konig,, A. Neiss,, H. Bogaerts,, H. L. Bock,, H. Sehulte-Wissermann,, M. Gahr,, R. Sehult,, J. U. Folkens,, W. Rauh,, and R. Clemens. 1996. Efficacy of acellular pertuss is vaccine in early childhood after household exposure. JAMA 275: 37 41.
92. Shvartzman, P.,, R. Mader,, and T. Stopler. 1989. Hemiated lumbar disc associated with pertussis. J. Fam. Pract. 28: 224 225.
93. Simondon, F.,, M. P. Preziosi,, A. Yam,, C. T. Kane,, L. Chabirand,, I. Iteman,, G. Sanden,, S. Mboup,, A. HolTenbach,, K. Knudsen,, N. Guiso,, S. Wassilak,, and M. Cadoz. 1997. A random· ized double-blind trial comparing a two·component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 15: 1606 1612.
94. Smith, S.,, and R. C. Tilton. 1996. Acute Bordetella pertussis infection in an adult. J. Clin. Microbiol. 34: 429 430.
95. Stehr, K.,, J. D. Cherry,, U. Heininger,, S. Schmitt-Grobe,, M. Uberall,, S. Laussucq,, T. Eckhardt,, M. Meyer,, R. Engelhardt,, and P. Christenson. 1998. A comparative efficacy trial in Germany in infants who received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP vaccine, or DT vaccine. Pediatrics. 101: 1 11.
96. Storsaeter, J.,, H. Hallander,, C. P. Farrington,, P. Olin,, R. Miillby,, and E. Miller. 1990. Sec· ondary analyses of the efficacy of two acellular pertuss is vaccines evaluated in a Swedish phase III trial. Vaccine 8: 457 461.
97. Trollfors, B.,, J. Taranger,, T. Lagergard,, L. Lind,, V. Sundh,, G. Zackrisson,, C. Lowe,, W. Blackwelder,, and J. B. Robbins. 1995. A placebo·controlled trial of a pertussis-toxoid vaccine. N. Engl. J. Med. 333: 1045 1050.
98. Thomanen, E., 1988. Bordetella pertussis adhesins, p. 75 94. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, Inc.. New York, N.Y..
99. Tuomanen, E.,, and A. Weiss. 1985. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory·epithelial cells. J. Infect. Dis. 152: 118 125.
100. Ui, M., 1988. The multiple biological activities of pertussis toxin. p. 121 146. In A. C. Wardlaw, and R. Parton (ed.), Pathogenesis and Immunity in Pertussis. John Wiley and Sons, Inc. New York. N.Y..
101. Ui, M., 1990. Pertussis toxin as a valuable probe for G-protein involvement in signal transduction, p. 45 78. In J. Moss, and M. Vaughan (ed.). ADP-Ribosylating Toxins and G Proteins. American Society for Microbiology, Washington. D.C..
102. Wadowsky, R. M.,, R. H. Michaels,, T. Libert,, L. A. Kingsley,, and G. D. Ehrlich. 1996. Multiplex PCR-based assay for detection of Bordetella pertussis in nasopharyngeal swab specimens. J. Clin. Microbial. 34: 2645 2649.
103. Weiss, A. A.,, E. L. Hewlett,, G. A. Myers,, and S. Falkow. 1983. Tn5-induced mutations affecting virulence factors of Bordetella pertussis. Infect. Immun. 42: 33 4l.
104. Wilson, R.,, R. Read,, M. Thomas,, A. Rutman,, K. Harrison,, V. Lund,, B. Cookson,, W. Goldman,, H. Lambert,, and P. Cole. 1991. Effects of Bordetella pertussis infection on human respiratory epithelium in vivo and in vitro. Infect. Immun. 59: 337 345.
105. Wright, S. W.,, K. M. Edwards,, M. D. Decker,, and M. H. Zeldin. 1995. Pertussis infection in adults with persistent cough. JAMA 273: 1044 1046.


Generic image for table
Table 1

Virulence factors of

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7
Generic image for table
Table 2

Results from seven acellular pertussis vaccine trials

Citation: Hewlett E. 1998. Reemerging Infections: Recent Developments in Pertussis, p 145-158. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 2. ASM Press, Washington, DC. doi: 10.1128/9781555816957.ch7

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error